Whalesbook
Consumer Wellness Se Maza Mazaa, Q4 Performance Solid!
Zydus Lifesciences ne Q4 mein, jo March 31, 2026 ko khatam hua, consolidated net profit mein zabardast 14.65% ka jump dikhaya hai. Ye figure ₹1592.9 crore tak pahunch gaya. Iska sabse bada reason hai unka consumer wellness business, jismein revenue ₹1463.3 crore raha, jo pichhle saal isi time ₹908.1 crore tha. Overall revenue bhi badhkar ₹7,587 crore ho gaya ₹6,527.9 crore se. Pharma business se bhi ₹5,643.6 crore aaye hain, jo 4.9% zyada hai. Poore saal FY26 ki baat karein toh net profit 15% badhkar ₹5,456.4 crore ho gaya FY25 ke ₹4,745.1 crore se. Annual revenue bhi ₹27,148.4 crore tak pahunch gaya.
Shareholders Ke Liye Khushkhabri: Buyback Aur Dividend!
Apne shareholders ko reward karne ke liye, Zydus Lifesciences ne ₹1,100 crore ka share buyback program approve kiya hai. Share ₹1,150 per share ke rate par buyback kiye jayenge. Ye decision dikhata hai ki company management apne stock valuation par confident hai aur investors ko paisa wapas dena chahti hai. Iske alawa, ₹1 per equity share ka final dividend bhi recommend kiya gaya hai, jo shareholder approval ke baad milega. Khayal rahe, buyback price ₹1,150 hai, jo Monday, May 18, 2026 ko company ke closing price se lagbhag 16% upar hai.
Sector Peers Ke Muqable Valuation Kaise Hai?
Filhaal Zydus Lifesciences ka Price-to-Earnings (P/E) ratio lagbhag 19.53 hai, jise 'fair' mana ja raha hai aur sector averages ke hisab se bilkul theek hai. Ye valuation Sun Pharma, Lupin, Cipla, aur Dr. Reddy's Laboratories jaise competitors ke muqable mein competitive hai, jinka P/E ratio 19.41 se 72.40 ke beech hai. Zydus ka P/E shayad competitors se kam hai, lekin unke growth prospects par nazar rakhi ja rahi hai. PEG ratio 1.36 suggest karta hai ki future growth stock mein moderate price par reflect ho rahi hai. Company ki market capitalization lagbhag ₹101,831 crore hai.
Analysts Kya Kehte Hain Aur Future Kya Hai?
Analysts ka Zydus Lifesciences par view mila-jula hai, jismein consensus 'Neutral' rating ka hai. Abhi, 12 analysts 'Buy' karne ko keh rahe hain, 7 'Sell' karne ko, aur 10 'Hold' karne ko. Average 12-month price target lagbhag ₹1020 hai, jo recent trading levels se lagbhag 9.6% ka upside potential dikhata hai. Company management bhi confident hai aur unka kehna hai ki strong product pipeline hai aur recent acquisitions ko integrate karna aur synergies realize karna unki priorities hain. FY27 ke liye future guidance investors ke liye ek important factor hogi.
Potential Risks Aur Strategy Ka Focus
Acchi financial results ke bawajood, pharma sector mein global competition aur regulatory scrutiny jaise risks hamesha rehte hain. Zydus Lifesciences ka balance sheet mazboot hai, jismein debt-to-equity ratio sirf 0.09 hai. Lekin, kisi khaas market ya treatment par dependence future mein problem create kar sakti hai. Company ki growth strategy mein organic expansion aur strategic acquisitions dono shamil hain, isliye recent purchases, jaise Assertio Holdings, ka successful integration future returns ke liye bahut zaruri hai. Company ke future guidance par nazar rahegi, khaaskar ke key products par potential price competition aur badhte R&D expenses ko lekar.